High Collagen Type VI Formation Is a Strong and Independent Predictor of Poor Prognosis in HFpEF

Time: 2:00 pm
day: Conference Day 2


  • HFpEF is a highly heterogenous disease & patient stratification is essential to inform clinical trial
  • Meta-analysis data demonstrated strong, independent prognostic value of PRO-C6 as a novel biomarker in HFpEF (NEJM Evidence 2022)
  • FDA issued Letter of Support (LoS) to encourage further PRO-C6 work in HFpEF